香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公司董事（「董事」）會（「董事會」）欣然知會本公司股東（「股東」）及潛在投資 者，基於對本集團截至2025年6月30日止六個月（「報告期」）的未經審核綜合管理 賬目的初步評估以及對目前所得最新資料的評估，預期本集團將於報告期錄得利 潤不少於人民幣20.0百萬元，而2024年同期則錄得虧損約人民幣44.9百萬元。 本公司於報告期內轉虧為盈，主要基於三項授權合作的里程碑收入和商業化產品 的銷售收入，具體合作詳情可分別參閱本公司日期為2024年1月25日、2024年6月 5日以及2024年9月29日的公告。 （股份代號：9966） 正面盈利預告 本公告乃由康寧傑瑞生物製藥（「本公司」，連同其附屬公司統稱「本集團」）根據 《香港聯合交易所有限公司證券上市規則》（「《上市規則》」）第13.09(2)(a)條及香港 法例第571章《證券及期貨條例》第XIVA部項下的內幕消息條文（定義見《上市規 則》）作出。 AL ...

格隆汇8月12日丨康宁杰瑞制药-B(09966.HK)公布，公司将于2025年8月28日召开董事会会议，以（其中 包括）审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY 承董事會命 康寧傑瑞生物製藥 董事長兼執行董事 徐霆博士 香港，2025年8月12日 於本公告日期，董事會包括董事長兼執行董事徐霆博士及執行董事劉陽女士；非 執行董事左敏先生；及獨立非執行董事黃欣琪女士、高翔博士及吳冬先生。 康寧傑瑞生物製藥 （於開曼群島註冊成立的有限公司） （股份代號：9966） 董事會會議日期 康寧傑瑞生物製藥（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，本公司將 於2025年8月28日（星期四）舉行董事會會議，藉以（其中包括）考慮及通過本公司 及其附屬公司截至2025年6月30日止六個月之中期業績及其發佈，以及處理其他 事項。 ...

Group 1 - The core viewpoint of the article highlights a significant rise in energy storage concept stocks in the Hong Kong stock market, with Longpan Technology experiencing a surge of nearly 29% and Ruipu Lanjun rising over 23% [1]

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) has entered into a technology development contract with its wholly-owned subsidiary Jiangsu Corning Jereh Biopharmaceutical Co., Ltd. and Suzhou Corning Jereh Biotechnology Co., Ltd. to enhance its development of bispecific antibody-drug conjugates (ADCs) [1] Group 1 - The contract, signed on August 8, 2025, involves Suzhou Corning Jereh providing technical development services, including the development of production processes and analytical methods for ADC candidates [1] - Suzhou Corning Jereh has been a reliable service provider since 2018, possessing extensive experience and competitiveness in process optimization services [1] - The company believes that the contract will help optimize existing production and R&D processes, reduce related costs, and positively impact future product development, manufacturing, and IND applications [1]

Core Viewpoint - Corning Pharmaceutical-B (09966) has entered into a technology development contract with its wholly-owned subsidiary Jiangsu Corning Pharmaceutical and Suzhou Corning Pharmaceutical, aimed at enhancing the development and production processes of its bispecific antibody-drug conjugate (ADC) candidates [1] Group 1 - Jiangsu Corning Pharmaceutical has commissioned Suzhou Corning Pharmaceutical to provide technical development services, including the development of production processes and analytical methods for ADC candidates [1] - The contract includes the preparation of samples for toxicology studies and the development of clinical trial samples for IND submission, as well as quality and stability studies of related samples [1] - Suzhou Corning Pharmaceutical has extensive experience and competitiveness in process optimization services, having been a reliable service provider for the company since 2018, which enhances familiarity with the company's needs [1] Group 2 - The company believes that the quality of services provided by Suzhou Corning Pharmaceutical, along with the convenience and confidentiality of future technology transfers, will optimize existing production and R&D processes [1] - The competitive pricing of the services compared to other independent third-party suppliers is expected to lower related costs and positively impact the company's product development, manufacturing, and IND applications in the foreseeable future [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 關連交易公告 與蘇州康寧傑瑞的技術開發合作 本公告由康寧傑瑞生物製藥（「本公司」，連同其附屬公司統稱「本集團」）根據香 港聯合交易所有限公司證券上市規則（「上市規則」）第14A章下的關連交易條文作 出。 緒言 本公司董事會（「董事會」）欣然宣佈，本公司全資附屬公司江蘇康寧傑瑞生物製藥 有限公司（「江蘇康寧傑瑞」）與蘇州康寧傑瑞生物科技有限公司（「蘇州康寧傑瑞」） 於2025年8月8日訂立一份技術開發合同（「技術開發合同」），據此，江蘇康寧傑瑞 已同意委聘蘇州康寧傑瑞提供技術開發服務，而蘇州康寧傑瑞將（其中包括）為江 蘇康寧傑瑞的雙特異性抗體偶聯藥物（「ADC」）候選藥物（「候選藥物」）進行生產 工藝及分析方法開發、進行毒理研究用樣品研製及新藥臨床試驗（「IND」）申報臨 床樣品研製，對相關樣品進行質量及穩定性研究，並協助進行IND註冊申報。 技術開發合同 ALPHAMAB ONCOLOGY 康寧傑瑞生物 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康寧傑瑞生物製藥 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09966 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 25,100,000,000 | USD | 0.000002 | USD | | 50,200 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 25,100,000,000 | USD | 0.000002 | USD | | 50,200 | 本月底法定/註冊股本總額： USD 50 ...

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) has announced that its self-developed PD-L1/Integrin αvβ6 bispecific antibody ADC, JSKN022, has received formal acceptance for clinical trial (IND) application by the National Medical Products Administration (NMPA) in China [1] Group 1: Product Development - The company plans to initiate the first human clinical study of JSKN022 for the treatment of advanced malignant solid tumors [1] - Currently, there are no ADCs targeting Integrin αvβ6 or PD-L1 available on the market globally, and related investigational drugs are still in clinical research stages [1] Group 2: Clinical Data - Preclinical data indicates that JSKN022 exhibits anti-tumor activity against tumor cells expressing Integrin αvβ6 and/or PD-L1 in both in vitro and in vivo models [1] - The drug is expected to provide new treatment options for patients with tumors that are resistant to or ineffective against PD-1/PD-L1 inhibitors, such as non-small cell lung cancer, head and neck squamous cell carcinoma, and colorectal cancer [1]

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) has received formal acceptance from the National Medical Products Administration (NMPA) for its Investigational New Drug (IND) application for JSKN022, a dual-specific antibody-drug conjugate (ADC) targeting programmed cell death ligand 1 (PD-L1) and integrin αvβ6, aimed at treating advanced malignant solid tumors [1] Group 1 - The company plans to initiate the first human clinical study of JSKN022 for the treatment of advanced malignant solid tumors [1] - Currently, there are no ADCs targeting integrin αvβ6 or PD-L1 available on the global market, with all related investigational drugs still in clinical research stages [1] - Preclinical data indicates that JSKN022 exhibits anti-tumor activity against tumor cells expressing integrin αvβ6 and/or PD-L1 in both in vitro and in vivo models [1] Group 2 - JSKN022 is expected to provide new treatment options for patients with tumors that are resistant to or ineffective against PD-1/PD-L1 inhibitors, such as non-small cell lung cancer, head and neck squamous cell carcinoma, and colorectal cancer [1]